Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study

Am J Med Genet A. 2019 Jun;179(6):1069-1073. doi: 10.1002/ajmg.a.61105. Epub 2019 Mar 28.

¹ Lysosomal Storage Disorders Unit, Royal Free NHS Foundation Trust and University College London, London, United Kingdom.
² Department of Nephrology, Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia.
³ Division of Nephrology and Dialysis, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
⁴ The Mark Holland Metabolic Unit, Salford Royal Hospital and NHS Foundation Trust, Salford, United Kingdom.
⁵ Department of Medical Endocrinology and Metabolism, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
⁶ Metabolic Disease, Baylor Research Institute, Dallas, Texas.
⁷ Medical Genetics Service, HCPA, and Department of Genetics, UFRGS, Porto Alegre, Rio Grande do Sul, Brazil.
⁸ Amicus Therapeutics, Inc., Cranbury, New Jersey.
⁹ Departments of Medicine and Physiology, Hôpital du Sacré-Coeur, University of Montreal, Montreal, Quebec, Canada.

No abstract available

Publication types